New pharmacological tools:the use of diterpenes to promote adult hippocampal neurogenesisRicardo Gómez-Oliva, Pedro Nunez-Abades, Carmen Castro1629-1630
Clustering of voltage-gated ion channels as an evolutionary trigger of myelin formationHenrike Ohm, Simone Rey, Christian Klämbt1631-1632
Using microglia-derived extracellular vesicles to capture diversity of microglial activation phenotypes following neurological injuryAustyn D.Roseborough, Nikita Ollen-Bittle, Shawn N.Whitehead1633-1634
Sexual dimorphism of G protein-coupled receptor signaling in the brainSara Aljoudi, Hamdan Hamdan, Khaled S.Abd-Elrahman1635-1636
Glycolysis and glucose metabolism as a target for bioenergetic and neuronal protection in glaucomaPete A.Williams, Robert J.Casson1637-1638
MAP4K inhibition as a potential therapy for amyotrophic lateral sclerosisShuaipeng Ma, Chun-Li Zhang1639-1640
Role of fullerenols derivative 3HFWC in the treatment of Alzheimer's diseaseSanja Ivkovic, Djuro Koruga1641-1642
Monomeric C-reactive protein:a link between chronic inflammation and neurodegeneration?Nicoleta Arnaut, Ylenia Pastorello, Mark Slevin1643-1644
Alterations of protein homeostasis in Alzheimer's disease:beyond Procrustean bed of endoplasmic reticulum stress and unfolded protein responseDmitry Lim, Alexei Verkhratsky1645-1646
The big data challenge-and how polypharmacology supports the translation from pre-clinical research into clinical use against neurodegenerative diseases and beyondSven Marcel Stefan, Muhammad Rafehi1647-1648
